SELECTED IMPORTANT SAFETY INFORMATION
- Some people who have taken medicine like ATRIPLA have developed build up of lactic acid in the blood, which can be a serious medical emergency that can lead to death.
Some people who have taken medicines like ATRIPLA have developed
serious liver problems, with liver enlargement and fat in the liver, which can lead to death.
- If you also have hepatitis B virus (HBV) infection and you stop taking ATRIPLA, your hepatitis may suddenly
get worse. ATRIPLA is not approved for the treatment of HBV.
Please
click here for more information about these warnings, including signs and symptoms, and other Important Safety Information.
THIS PAGE IS UNDER CONSTRUCTION
Click here for ATRIPLA Full Prescribing Information.
(c) 2012 Bristol-Myers Squibb Company.
ATRIPLA and ATRIPLA Peer Advocate Network are registered trademarks of Bristol-Myers Squibb & Gilead Sciences, LLC. SUSTIVA is a registered trademark of Bristol-Myers Squibb Company. COMPLERA, EMTRIVA, GILEAD, GSI, HEPSERA, TRUVADA, and VIREAD are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.
Patient models are used on this Web site. The information on this site is intended for residents of the United States who are 18 years of age or older. The content of this site is protected under applicable copyright and trademarks law.
This site may contain, from time to time, information related to various health, medical and fitness conditions, and their treatment. Such information is not meant to be a substitute for the advice provided by a physician or other medical professional. You should not use the information contained herein for diagnosing a health or fitness problem or disease. You should always consult a physician and/or a healthcare provider.
Your use of this information is subject to the terms and conditions of our
Terms of Use and
Privacy Policy.
697US12WA04601 07/12